A 58-year-old woman with COPD GOLD stage II (FEV₁ 55% predicted) on maintenance therapy (tiotropium + salbutamol PRN) presents with 2 exacerbations in the past 12 months. She denies current dyspnea or fever. Spirometry today: FEV₁ 52% predicted (baseline 55%). What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **frequent exacerbations** (≥2 per year) despite being on a single long-acting agent (LAMA: tiotropium). Recurrent exacerbations are a key driver of COPD progression and mortality, and escalation of pharmacotherapy is warranted. ## GOLD Classification & Escalation Strategy **Key Point:** GOLD 2023 recommends escalating therapy based on **exacerbation history and symptoms**, not FEV₁ alone. Patients with ≥2 exacerbations per year should receive triple therapy (LABA + LAMA + ICS) or at minimum dual therapy with LABA + LAMA. **High-Yield:** Triple therapy (LABA/LAMA/ICS) is superior to monotherapy or dual therapy in reducing exacerbation frequency and mortality in patients with recurrent exacerbations and/or chronic bronchitis/emphysema with airway inflammation. ## COPD Pharmacotherapy Escalation Algorithm ```mermaid flowchart TD A[COPD patient on maintenance therapy]:::outcome --> B{Exacerbations per year?}:::decision B -->|0 exacerbations| C[Continue current therapy]:::action B -->|≥1 exacerbation| D{Symptoms/FEV₁ decline?}:::decision D -->|Minimal| E[Add LABA to LAMA]:::action D -->|Yes or ≥2 exacerbations| F[Triple therapy: LABA + LAMA + ICS]:::action F --> G[Reassess in 3-4 weeks]:::action G -->|Inadequate response| H[Consider PDE-4 inhibitor or macrolide]:::action ``` ## Therapy Comparison | Regimen | Indication | Exacerbation Reduction | |---|---|---| | LAMA monotherapy | Mild-moderate COPD, no exacerbations | Baseline | | LABA + LAMA | 1 exacerbation/year OR persistent symptoms | ~20–25% | | LABA + LAMA + ICS | ≥2 exacerbations/year OR with asthmatic features | ~25–35% | | Triple + PDE-4 inhibitor | Chronic bronchitis phenotype, frequent exacerbations | Additional ~10–15% | ## Rationale for Correct Answer This patient meets criteria for triple therapy because: 1. **≥2 exacerbations in 12 months** (key trigger for escalation) 2. **Inadequate control on monotherapy** (LAMA alone) 3. **No contraindications to ICS** (no documented non-tuberculous mycobacteria, no recurrent lower respiratory infections) Triple therapy (LABA/LAMA/ICS combination inhalers) is the evidence-based next step and offers the greatest exacerbation reduction. **Clinical Pearl:** ICS in COPD is indicated for patients with asthma-COPD overlap features or frequent exacerbations (≥2/year), as it reduces exacerbation risk and mortality. The combination inhaler improves adherence compared to separate devices. [cite:GOLD 2023 Report; Harrison 21e Ch 254]